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See related article on page 34.doi:10.1016/j.jtcvs.2005.05.027In the 40 years since its introduction into clinical practice, the role of glucose-insulin-potassium (GIK) during cardiac surgery has remained undefined.1 Al-though there is growing evidence that hyperglycemia is detrimental and insulin
therapy is beneficial to the diabetic patient during cardiac surgery, the significance
of hyperglycemia in the nondiabetic cardiac surgical patient and the potential
benefits of GIK are still the subject of intense debate.
In a recent issue of the Journal, Doenst and coworkers2 provide evidence that
hyperglycemia is an independent predictor of perioperative morbidity and mortality
in both diabetic and nondiabetic patients. Their study is unique in that they chose to
assess the highest glucose level during cardiopulmonary bypass (CPB) as an
independent variable rather than postoperative glucose levels. They hypothesized
that this measurement would reflect perioperative insulin resistance and would not
be influenced by inotropic agents. Their data corroborate our own work and that of
others showing that diabetic patients with increased perioperative glucose levels
(200 mg/dL) have poorer outcomes after cardiac surgery.3-5 There is no contro-
versy in these findings because all cardiac surgeons now agree that maintaining
serum glucose levels at less than 200 mg/dL is the standard of practice for all
diabetic patients in the perioperative period. The most optimal serum glucose level,
length of treatment, contents of the insulin solution, and mechanisms responsible for
these beneficial effects are now the subject of clinical investigations by our own
group and other investigators.
Although there is no controversy regarding the detrimental effects of hypergly-
cemia and the benefits of insulin in the diabetic patient, the effects of hyperglycemia
and the need for insulin therapy in the nondiabetic patient undergoing cardiac surgery
are still the subject of debate. One of the shortcomings of the study by Doenst and
coworkers2 is that the authors fail to distinguish between nondiabetic patients who
exhibit the normal response of insulin resistance on CPB and those patients with either
the metabolic syndrome or undiagnosed diabetes. For example, patients without
diabetes who exhibit insulin resistance during CPB will have normal glucose levels
after CPB in the intensive care unit (ICU). In fact, it has been our experience that
hypoglycemia might develop in these patients if they are vigorously treated with
insulin during CPB to obtain more normal glucose levels. These patients would be
less likely to exhibit an increased incidence of postoperative morbidity and mor-
tality. Patients with persistent hyperglycemia after surgical intervention in the ICU
(200 mg/dL) might represent a different population more prone to postoperative
morbidity. Indeed, in the series by Doenst and coworkers,2 patients with increased
glucose levels undergoing CPB were more likely to have reduced ejection fractions,
congestive heart failure, cardiogenic shock, and renal failure and require reopera-
tions or more urgent operations. Chronic insulin resistance has been shown to be a
risk factor for atherosclerotic disease.6 Could it be that these patients were diabetic
subjects who were not given diagnoses preoperatively? One way to resolve this
issue would have been to correlate the peak CPB glucose levels with postoperative
ICU glucose levels in the nondiabetic patients. I suspect that nondiabetic patients
who did not have persistently increased postoperative glucose levels would be less
likely to have experienced increased mortality and morbidity. These additional data
would likely determine the significance of hyperglycemia on CPB in the nondiabetic
patient. It would also have been important to know how many nondiabetic patients
with increased peak glucose levels undergoing CPB went on to be given diagnoses
of diabetes in the year after their cardiac surgery. Despite the numerous studies
The Journal of Thoracic and Cardiovascular Surgery ● Volume 131, Number 1 11
Editorials Lazar
ED
ITO
RIA
Lshowing that lower glucose levels are beneficial to cardiac
surgical patients, there are several studies, including our
own, demonstrating improved outcomes with systemic GIK
infusion, despite the fact that these solutions resulted in
systemic hyperglycemia.7,8 Hence, as noted by Doenst and
coworkers,2 it is still not clear whether hyperglycemia is a
risk factor in itself and whether its effect is the same in
diabetic and nondiabetic patients.
Another series that shows the beneficial effects of hy-
perglycemia with GIK infusion in nondiabetic patients ap-
pears in this issue of the Journal by Quinn and associates.9
The controversy surrounding GIK has been the result of inad-
equate studies characterized by lack of randomization, small
series of patients, inadequate study design with inconsisten-
cies in inclusion criteria, and differences in composition,
volume, and duration of GIK infusions. Furthermore, most
studies had perioperative mortality as the primary end point,
which might not be attainable in today’s practice of cardiac
surgery. In their study Quinn and associates have addressed
these shortcomings. Their study design was a prospectively
randomized, double-blind, placebo-controlled trial consist-
ing of 280 nondiabetic adult patients undergoing primary
CABG surgery. Diabetic patients were excluded. The GIK
solution consisted of D40W plus 70 U of insulin plus 80
mEq of KCl at 0.75 mL · kg1 · h1 beginning at anesthetic
induction and continuing for 6 hours after the operation. The
primary end point was postreperfusion cardiac index. GIK-
treated patients had higher cardiac indices (P  .001),
reduced vascular resistance (P  .001), and a lower inci-
dence of low cardiac output syndrome (15.9% vs 27.5%,
P  .021). They required less inotropic support (18.8% vs
40.8%, P  .001) and had less evidence of myocardial
injury, as defined as a perioperative myocardial infarction
and enzyme release (12.3% vs 23.4%, P  .017). The
beneficial effects were seen in both high-risk patients and in
those with low ejection fractions, as well as in low-risk
patients and patients with hyperglycemia during the GIK
infusion. There was, however, no difference in the incidence
of atrial fibrillation or length of hospital stay. These results
are almost identical to those of our own series in nondia-
betic patients, which showed that GIK not only improved
myocardial performance and decreased the need for inotro-
pic support but also decreased the incidence of atrial fibril-
lation and hospital length of stay.7 I suspect that the bene-
ficial effect of GIK on lowering the incidence of atrial
fibrillation was not observed in this series because the GIK
infusion lasted for only 6 hours postoperatively and because
-blockers were not instituted until the fourth postoperative
day. This undoubtedly accounted for the high incidence of
atrial fibrillation (55%) seen in this series. Similar to our
own results, patients receiving GIK had higher postopera-
tive serum glucose levels, but this did not result in any
adverse outcomes. These data are also consistent with the
12 The Journal of Thoracic and Cardiovascular Surgery ● Januameta-analysis by Bothe and colleagues,8 who found that
GIK resulted in a significant improvement of postoperative
contractible function and significantly reduced the incidence
of postoperative atrial fibrillation.
What can we conclude from these 2 studies regarding the
role of hyperglycemia and GIK in the cardiac surgical
patient? Hyperglycemia in the diabetic patient is reflective
of chronic insulin resistance, is predictive of poor outcomes,
and should be aggressively treated. Hyperglycemia in non-
diabetic subjects, which occurs only during CPB, is most
likely reflective of acute insulin resistance and might not be
associated with poor outcomes if glucose levels return to
less than 200 mg/dL immediately after surgical interven-
tion. Hyperglycemia (200-240 mg/dL) associated with GIK
infusion in nondiabetic patients does not have the same
negative prognostic finding seen in diabetic patients because
of the protective effects of simultaneous insulin infusion.
Should GIK be given to all patients, both diabetic and
nondiabetic, undergoing cardiac surgery? The 2 studies
presented in this issue of the Journal make a strong point in
favor of using GIK in all patients. It is simple to administer,
inexpensive, and has virtually no side effects. In diabetic
patients we use 500 mL of 5% dextrose in water plus 80 U
of insulin plus 40 mEq of KC1 titrated to an algorithm
designed to keep serum glucose levels between 120 and 180
mg/dL. The solution is started during anesthetic induction
and continued for 18 hours after the operation, at which time
the patient’s previous diabetic regimen is resumed. For
nondiabetic patients, we use 30% dextrose in water plus
50 U of regular insulin plus 80 mEq of KC1 to run at 0.75
mg · kg1 · h1, with supplemental intravenous insulin ad-
ministered to keep serum glucose levels at 200 mg/dL or
less. This solution is also continued for 18 hours after the
operation. All patients receiving GIK have their glucose
levels checked on an hourly basis and more frequently if
adjustments in infusion rates are made. I suspect that the
GIK 30% dextrose in water will have its greatest effect in
nondiabetic patients undergoing coronary artery bypass
grafting (CABG) requiring urgent operations with ejection
fractions of less than 50%, those with recent myocardial
infarctions, and those with acute coronary syndromes. How-
ever, because the incidence of atrial fibrillation is decreased,
it could result in a decrease in length of stay of nearly 2 days
in all patients.
I believe that there are enough data to recommend the use
of GIK in all cardiac surgery patients, both diabetic and
nondiabetic. However, to end any controversy, now might
be the time to consider a multicenter trial to resolve this
issue. Because the detrimental effects of hyperglycemia in
diabetic patients is already well established, it would be
unethical to randomize these patients to a control group
without insulin therapy. The trial would consist of nondia-
betic patients undergoing CABG surgery. The type of GIK
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Lsolution used and the duration of treatment would be stan-
dardized. The primary end point would be the composite
end points of death, myocardial infarction, cardiac index,
and need and duration of inotropic support. Secondary end
points would include weight gain, time to extubation, ICU
and hospital length of stay, incidence of wound infections,
and atrial fibrillation. There would be a 1-year follow-up to
record the incidence of ischemic events, which would in-
clude angina, death, strokes, congestive heart failure, and
the need for a repeat revascularization procedure. Such a
trial would put an end to the GIK controversy and hopefully
the need for further editorials.
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